ELEVEN THERAPEUTICS
Eleven Therapeutics is a research firm that unleashes the power of RNAi technology that helps to create precise and durable therapeutics.
ELEVEN THERAPEUTICS
Industry:
Biotechnology Medical Product Research Therapeutics
Founded:
2020-01-01
Address:
Tel Aviv, Tel Aviv, Israel
Country:
Israel
Website Url:
http://www.eleventx.com
Total Employee:
1+
Status:
Active
Total Funding:
26.3 M USD
Current Employees Featured
Iris Grossman Chief Strategy Officer (CSO) @ Eleven Therapeutics
Chief Strategy Officer (CSO)
2021-09-01
Investors List
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation investment in Seed Round - Eleven Therapeutics
Kindred Capital
Kindred Capital investment in Seed Round - Eleven Therapeutics
NFX Bio
NFX Bio investment in Seed Round - Eleven Therapeutics
Harel Insurance Investments and Financial Services
Harel Insurance Investments and Financial Services investment in Seed Round - Eleven Therapeutics
Entrée Capital
Entrée Capital investment in Seed Round - Eleven Therapeutics
Innovate UK
Innovate UK investment in Seed Round - Eleven Therapeutics
Innovate UK
Innovate UK investment in Grant - Eleven Therapeutics
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation investment in Grant - Eleven Therapeutics
Official Site Inspections
http://www.eleventx.com Semrush global rank: 4.94 M Semrush visits lastest month: 1.74 K
- Host name: 567510.cloudwaysapps.com
- IP address: 178.62.216.55
- Location: Amsterdam Netherlands
- Latitude: 52.352
- Longitude: 4.9392
- Timezone: Europe/Amsterdam
- Postal: 1098
More informations about "Eleven Therapeutics"
About Us - Eleven Therapeutics
We are a cross-disciplinary group of entrepreneur-scientists that came together in 2020 to usher in the next generation of RNA technologies. Coming from leading academic institutions, well …See details»
Eleven Therapeutics - Crunchbase Company Profile
Eleven Therapeutics is a biotechnology company at the forefront of the artificial intelligence revolution in medicinal nucleic acids. The new generation of RNAi therapies is introduced by merging artificial intelligence, parallel functional …See details»
Eleven Therapeutics Company Profile 2024: Valuation, …
Information on valuation, funding, cap tables, investors, and executives for Eleven Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Eleven Therapeutics - LinkedIn
Iris Grossman, PhD Chief Therapeutics Officer (CTxO) at Eleven Therapeutics; Lead Pharmaceutical Science, Pipeline and Partnerships; Scientific Board Member and chair;…See details»
Eleven Therapeutics - Overview, News & Similar companies
Aug 1, 2022 Who is Eleven Therapeutics. Eleven Therapeutics is a cross-disciplinary group of entrepreneur-scientists that came together in 2020 to usher in the next generation of RNAi tec …See details»
Eleven Tx - Craft
Eleven Tx has 5 employees across 3 locations and $22 m in total funding,. See insights on Eleven Tx including office locations, competitors, revenue, financials, executives, subsidiaries and …See details»
Eleven Therapeutics | Devex
Learn more about Eleven Therapeutics's jobs, projects, latest news, contact information and geographical presence. They are a cross-disciplinary group of entrepreneur-scientists that …See details»
Eleven Tx CEO and Key Executive Team | Craft.co
Eleven Tx's CEO and Co-Founder is Yaniv Erlich. Other executives include Shaul Ilan, COO and Co-Founder; Greg Hannon, Scientific Co-Founder. See the full leadership team at Craft.See details»
Eleven Therapeutics Appoints Prominent Biopharma Leader Dr.
Feb 10, 2022 Prof. Yaniv Erlich Chief Executive Officer and Co-Founder Email: yaniv@eleventx.com. Dr. Iris Grossman Chief Strategy Officer Email: iris@eleventx.com--- …See details»
Eleven Therapeutics Welcomes Dr. Paloma H …
Jan 11, 2024 Eleven Therapeutics, a pioneering biotechnology company specializing in next-generation mRNA therapeutics, proudly announces the appointment of Dr. Paloma H Giangrande as the company's Chief ...See details»
Adi Gilboa-Geffen Joins Management of Eleven Therapeutics
Oct 15, 2024 Dr. Adi Gilboa-Geffen Joins Eleven Therapeutics as SVP of Product R&D, Advancing the Future of xRNA Therapeutics. May 16, 2023 [BOSTON, U.S. and …See details»
Eleven Therapeutics Announces $22 Million in Seed Funding - PR …
Aug 2, 2022 Round includes $9 Million from the Bill & Melinda Gates Foundation, aimed at ushering in the next generation of RNAi therapeutics . TEL AVIV, Israel and CAMBRIDGE, …See details»
Careers - Eleven Therapeutics
We are un-disciplined * scientists. * Un-disciplined (ən-ˈdi-sə-plənd): a scientist who is skilled in the craft of moving across disciplines in order to solve problems without a slight compromise …See details»
Eleven Therapeutics Recognized as One of the 50 Most Promising …
May 11, 2023 The biotech company develops groundbreaking technology for programmable RNA drug development via AI and combinatorial chemistry [CAMBRIDGE, UK and TEL AVIV, …See details»
Technology - Eleven Therapeutics
Our patent-pending orthogonal chemistry coupling simultaneously synthesizes the modified RNA oligo and the DNA barcode. In the illustration, the left column uses 2′-F Uridine as the first …See details»
Eleven Therapeutics Pursues Cooperative Research and ... - Medium
Oct 15, 2024 Prof. Yaniv Erlich Chief Executive Officer and Co-Founder Email: yaniv@eleventx.com----Follow. Written by Eleven Therapeutics. 26 Followers. Follow. More …See details»
Eleven Therapeutics Appoints Prominent Biopharma Leader Dr. Iris ...
Eleven Therapeutics Receives $3.9 Million for Development of Innovative Treatments Against Respiratory VirusesSee details»
News - Eleven Therapeutics
Eleven Therapeutics Announces Research Collaboration with Novo Nordisk to Discover Cell-Specific Carriers of Nucleic Acid Therapeutics. Read MoreSee details»
ELeveNote. how we created our proprietary… | by Eleven ... - Medium
Dec 11, 2023 Due to popular demand, we created two free resources for the biotech community: 1. A live demo that lets you see what ELeveNote looks like first-hand 2. A Notion template that …See details»